These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 32647050)

  • 1. Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K.
    Roze S; Isitt J; Smith-Palmer J; Javanbakht M; Lynch P
    Diabetes Care; 2020 Oct; 43(10):2411-2417. PubMed ID: 32647050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring system in people with type 1 diabetes in Australia.
    Isitt JJ; Roze S; Tilden D; Arora N; Palmer AJ; Jones T; Rentoul D; Lynch P
    Diabet Med; 2022 Jul; 39(7):e14831. PubMed ID: 35298036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Cost-Effectiveness the Dexcom G6 Real-Time Continuous Glucose Monitoring System Compared with Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in France.
    Roze S; Isitt JJ; Smith-Palmer J; Lynch P; Klinkenbijl B; Zammit G; Benhamou PY
    Diabetes Ther; 2021 Jan; 12(1):235-246. PubMed ID: 33165838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Long-Term Cost-Effectiveness of the Dexcom G6 Continuous Glucose Monitor versus Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in Canada.
    Roze S; Isitt JJ; Smith-Palmer J; Lynch P
    Clinicoecon Outcomes Res; 2021; 13():717-725. PubMed ID: 34408456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France.
    Alshannaq H; Pollock RF; Joubert M; Ahmed W; Norman GJ; Lynch PM; Roze S
    J Comp Eff Res; 2024 Mar; 13(3):e230174. PubMed ID: 38294332
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose and intermittently scanned continuous glucose monitoring in people with type 1 diabetes receiving multiple daily insulin injections in Denmark.
    Alshannaq H; Cogswell G; Pollock RF; Ahmed W; Norman GJ; Lynch PM; Roze S
    Diabetes Obes Metab; 2023 Sep; 25(9):2704-2713. PubMed ID: 37334522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type 2 diabetes in Canada.
    Alshannaq H; Isitt JJ; Pollock RF; Norman GJ; Cogswell G; Lynch PM; Roze S
    J Comp Eff Res; 2023 Oct; 12(10):e230075. PubMed ID: 37668608
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial.
    Wan W; Skandari MR; Minc A; Nathan AG; Winn A; Zarei P; O'Grady M; Huang ES
    Diabetes Care; 2018 Jun; 41(6):1227-1234. PubMed ID: 29650803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: A microsimulation model and cost-effectiveness analysis from a US perspective with relevance to Medicaid.
    Frank J; Son D; Szafranski K; Poon Y
    J Manag Care Spec Pharm; 2024 Sep; 30(9):917-928. PubMed ID: 39109990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of G5 Mobile continuous glucose monitoring device compared to self-monitoring of blood glucose alone for people with type 1 diabetes from the Canadian societal perspective.
    Chaugule S; Graham C
    J Med Econ; 2017 Nov; 20(11):1128-1135. PubMed ID: 28745578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Cost-Effectiveness of Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Adults With Type 1 Diabetes in Iran.
    Molaee MC; Naseri ZG; Karami MA
    Value Health Reg Issues; 2024 Sep; 43():101002. PubMed ID: 38820700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time continuous glucose monitoring vs. self-monitoring of blood glucose: cost-utility in South Korean type 2 diabetes patients on intensive insulin.
    Kim JY; Ilham S; Alshannaq H; Pollock RF; Ahmed W; Norman GJ; Jin SM; Kim JH
    J Med Econ; 2024; 27(1):1245-1252. PubMed ID: 39275990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK.
    Isitt JJ; Roze S; Sharland H; Cogswell G; Alshannaq H; Norman GJ; Lynch PM
    Diabetes Ther; 2022 Dec; 13(11-12):1875-1890. PubMed ID: 36258158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK.
    Roze S; Buompensiere MI; Ozdemir Z; de Portu S; Cohen O
    J Med Econ; 2021; 24(1):883-890. PubMed ID: 34098834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
    Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
    Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.
    Riemsma R; Corro Ramos I; Birnie R; Büyükkaramikli N; Armstrong N; Ryder S; Duffy S; Worthy G; Al M; Severens J; Kleijnen J
    Health Technol Assess; 2016 Feb; 20(17):v-xxxi, 1-251. PubMed ID: 26933827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
    Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
    J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost implications of continuous glucose monitoring in pregnant women with type 1 diabetes in 3 Canadian provinces: a posthoc cost analysis of the CONCEPTT trial.
    Ahmed RJ; Gafni A; Hutton EK; Hu ZJ; Sanchez JJ; Murphy HR; Feig DS;
    CMAJ Open; 2021; 9(2):E627-E634. PubMed ID: 34088734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of Dexcom G6 real-time continuous glucose monitoring versus FreeStyle Libre 1 intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in Belgium.
    Visser MM; Van Muylder A; Charleer S; Isitt JJ; Roze S; De Block C; Maes T; Vanhaverbeke G; Nobels F; Keymeulen B; Mathieu C; Luyten J; Gillard P; Verhaeghe N
    Diabetologia; 2024 Apr; 67(4):650-662. PubMed ID: 38236409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes.
    Fonda SJ; Graham C; Munakata J; Powers JM; Price D; Vigersky RA
    J Diabetes Sci Technol; 2016 Jul; 10(4):898-904. PubMed ID: 26843480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.